Company profile
Alzamend Neuro Inc
NASDAQ: ALZN · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 27
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$4.5M
Employees
6
as of 2026-08-24
Market cap
$5.9M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$4.5M-$4.5M2025
Operating income-$4.5M-$4.5M2025
Total assets$4.6M$4.6M2025
Liabilities$634.8k$634.8k2025
Equity$4.0M$4.0M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Alzamend Neuro Inc’s financial profile?
Alzamend Neuro Inc earned -$4.5M in FY2025 net income.
Peers · Healthcare
Reviva Pharmaceuticals Holdings, Inc.——Medicus Pharma Ltd. Common Stock——Adial Pharmaceuticals, Inc.——Cadrenal Therapeutics, Inc. Common Stock——CordovaCann Corp.——Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst——Neighbors
Fulton →Key facts
CEOStephan Jackman
SectorHealthcare
IndustryBiotechnology
HeadquartersAtlanta, GA
ExchangeNASDAQ: ALZN
Employees6
IPO date2021-06-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.